Innovent Biologics, Inc. Discovered novel IBI351/GFH925(KRASG12C Inhibitor) as monotherapy for the patients previously treated with advanced non-small cell lung cancer. It is applicable for patients with KRASG12C mutation who have received at least one prior line of systemic therapy.
The results for IBI351 are based on phase I/II trial and patients when treated with IBI351 monotherapy have shown safety, tolerability and promising antitumor activity with advanced solid tumors who failed or intolerant to standard of care treatment. KRAS mutations rarely co-exist with driver mutations such as EGFR and ALK.
Patients with NSCLC KRAS G12C mutation have very few treatment options. Hence, IBI351 has shown positive results in Phase 1 study for the treatment of advanced non-small cell lung cancer.
Lung cancer is the leading cause of global cancer and mortality with non-small cell lung cancer (NSCLC) is the most common pathological type accounting for about 85% of all lung cancers.
China’s National Medical Products Administration (NMPA) grants Breakthrough Therapy Designation (BTD) for IBI351 (GFH925) for the treatment of advanced non-small cell lung cancer patients with KRASG12C mutation that have received at least one prior line of systemic therapy.
